oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway
Department of Medical Sciences, Section of Clinical Microbiology, Uppsala University, Uppsala, Sweden.
Gastroenterology and Nutrition Research Group, Department of Clinical Medicine, UiT the Arctic University of Norway, Tromsø, Norway; Department of Medicine, University Hospital of North Norway, Tromsø, Norway.
Department of Medical Sciences, Section of Clinical Microbiology, Uppsala University, Uppsala, Sweden.
Institute of Biology II, University of Freiburg, Freiburg, Germany; Institute of Biology II, University of Freiburg, Freiburg, Germany.
Show others and affiliations
2019 (English)In: Scandinavian Journal of Gastroenterology, ISSN 0036-5521, E-ISSN 1502-7708Article in journal (Refereed) Epub ahead of print
Abstract [en]

Background: The NS5A resistance-associated substitution (RAS) Y93H is found quite frequently (5-10%) at baseline in direct-acting antiviral agents (DAA) treatment-naive genotype (GT) 3a patients when studied by the population-sequencing method (cut-off 20%). This RAS may impair HCV DAA treatment response, since it possesses a high fold in vitro resistance to daclatasvir (DCV) and velpatasvir (VEL) in GT 3. We investigated the effect of baseline Y93H in patients with GT 3a infection on treatment outcome, with or without resistance-based DAA-treatment during 2014-2017.

Patients/Methods: Treatment in the intervention group (n = 130) was tailored to baseline resistance-findings by population-sequencing method. Detection of baseline Y93H above 20% prompted a prolonged treatment duration of NS5A-inhibitor and sofosbuvir (SOF) and/or addition of ribavirin (RBV). Patients without baseline Y93H in the intervention group and all patients in the control group (n = 78) received recommended standard DAA-treatment.

Results: A higher sustained virologic response rate (SVR) in the intervention group was shown compared to the control group at 95.4% (124/130) and 88.5% (69/78), respectively (p = .06). All five patients with baseline Y93H in the intervention group achieved SVR with personalised treatment based on results from resistance testing; either with the addition of RBV or prolonged treatment duration (24w). In the control group, 2/4 patients with Y93H at baseline treated with ledipasvir/SOF/RBV or DCV/SOF without RBV, failed treatment.

Conclusion: The results from this real-life study are in accordance with the findings of the randomised controlled trials in 2015 and the EASL-guidelines of 2016, thus, baseline Y93H impacts on DCV and VEL treatment outcome.

Place, publisher, year, edition, pages
Taylor & Francis, 2019.
Keywords [en]
Baseline resistance, NS5A, Y93H, hepatitis C virus, resistance-associated substitution, sustained virologic response
National Category
Infectious Medicine Gastroenterology and Hepatology
Identifiers
URN: urn:nbn:se:oru:diva-75912DOI: 10.1080/00365521.2019.1652846ISI: 000481902500001PubMedID: 31424972OAI: oai:DiVA.org:oru-75912DiVA, id: diva2:1345992
Note

Funding Agencies:

Uppsala-Örebro Regional Research Council  RFR-651021  RFR-744511 

Erik, Karin and Gösta Selander Foundation  

Scandinavian Society for Antimicrobial Chemotherapy  SLS-692951 

Uppsala County Council  

Uppsala University 

Available from: 2019-08-26 Created: 2019-08-26 Last updated: 2019-09-04Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMed

Authority records BETA

Duberg, Ann-Sofi

Search in DiVA

By author/editor
Duberg, Ann-Sofi
By organisation
School of Medical Sciences
In the same journal
Scandinavian Journal of Gastroenterology
Infectious MedicineGastroenterology and Hepatology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 14 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf